Project Grant R01AI182297

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $802,798 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Research Foundation for the State University of New York (RF SUNY) to develop novel biamyxin antibiotics targeting multidrug-resistant gram-negative bacterial infections. The goal is to identify a qualified lead development candidate by Year 4 and pursue an Investigational New Drug (IND) candidate by Years 4-5. Key objectives include optimizing biamyxin potency and spectrum, evaluating pharmacological and toxicological properties, and demonstrating robust in vivo efficacy against carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates, including colistin-resistant strains. This work aims to address the urgent public health need for new antimicrobial agents to combat the growing threat of multidrug-resistant gram-negative bacterial infections.